High-Dose Wegovy Takes Aim at Lilly’s Zepbound
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) said its high-dose version of Wegovy has received a…
Ozempic Users Win Eye-Disease Payout in Novo’s Home Market
Four patients who developed a serious eye disease after using Novo Nordisk A/S’s blockbuster weight-loss drugs have been…